全文获取类型
收费全文 | 46049篇 |
免费 | 5554篇 |
国内免费 | 1173篇 |
专业分类
耳鼻咽喉 | 867篇 |
儿科学 | 6513篇 |
妇产科学 | 268篇 |
基础医学 | 3050篇 |
口腔科学 | 1409篇 |
临床医学 | 9587篇 |
内科学 | 4273篇 |
皮肤病学 | 447篇 |
神经病学 | 2840篇 |
特种医学 | 749篇 |
外国民族医学 | 2篇 |
外科学 | 2820篇 |
综合类 | 5181篇 |
现状与发展 | 2篇 |
一般理论 | 2篇 |
预防医学 | 8377篇 |
眼科学 | 1110篇 |
药学 | 3040篇 |
102篇 | |
中国医学 | 1405篇 |
肿瘤学 | 732篇 |
出版年
2024年 | 54篇 |
2023年 | 973篇 |
2022年 | 1207篇 |
2021年 | 2309篇 |
2020年 | 2544篇 |
2019年 | 2080篇 |
2018年 | 1886篇 |
2017年 | 2092篇 |
2016年 | 2176篇 |
2015年 | 1830篇 |
2014年 | 3166篇 |
2013年 | 4685篇 |
2012年 | 2777篇 |
2011年 | 2865篇 |
2010年 | 2372篇 |
2009年 | 2041篇 |
2008年 | 2020篇 |
2007年 | 2190篇 |
2006年 | 1903篇 |
2005年 | 1628篇 |
2004年 | 1357篇 |
2003年 | 1172篇 |
2002年 | 1052篇 |
2001年 | 908篇 |
2000年 | 680篇 |
1999年 | 550篇 |
1998年 | 524篇 |
1997年 | 440篇 |
1996年 | 385篇 |
1995年 | 353篇 |
1994年 | 332篇 |
1993年 | 266篇 |
1992年 | 223篇 |
1991年 | 207篇 |
1990年 | 179篇 |
1989年 | 170篇 |
1988年 | 149篇 |
1987年 | 109篇 |
1986年 | 142篇 |
1985年 | 109篇 |
1984年 | 79篇 |
1983年 | 79篇 |
1982年 | 75篇 |
1981年 | 65篇 |
1980年 | 61篇 |
1979年 | 53篇 |
1978年 | 39篇 |
1977年 | 36篇 |
1976年 | 57篇 |
1973年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
目的 系统评价弹性抗阻运动(弹力带/弹力管)对慢性阻塞性肺疾病(COPD)患者康复疗效的影响。方法 检索Cochrane Library、PubMed、Web of Science、中国知网、维普、万方和生物医学文献数据库中关于弹性抗阻运动治疗COPD患者的临床随机对照试验,检索时限自建库至2020年9月。最后纳入文献11篇,其中英文9篇,中文2篇,共485例患者。采用Cochrane风险偏倚评估工具及物理治疗证据数据库量表进行质量评价,采用RevMan 5.2软件进行分析。这一系统评价在PROSPERO(CRD42020208659)上登记。结果 弹性抗阻运动组与传统抗阻运动组(如举重训练机、体重训练) 6 min步行试验距离(6WMD) (MD = 1.19, 95%CI -7.02~9.39, P = 0.78)、COPD患者自我评估测试(CAT) (MD = -0.43, 95%CI -2.42~1.57, P = 0.68)和肌力(MD = 0.23, 95%CI -1.06~1.52, P = 0.73)无显著性差异,两组间异质性不高。弹性抗阻运动组与非抗阻运动组6MWD (MD = 18.30, 95%CI -8.92~45.52, P = 0.19)和CAT (MD = -0.59, 95%CI -3.78~2.60, P = 0.72)无显著性差异,研究间异质性较高。结论 弹性抗阻运动也许是一种潜在的替代传统抗阻训练的方法,但弹性抗阻运动对运动耐力、生活质量、肺功能的影响尚不明确。 相似文献
12.
13.
目的探讨阿奇霉素序贯给药辅助治疗小儿大叶性肺炎的效果及对患儿血清炎症因子水平的影响。方法回顾性分析我院2014年10月至2019年10月收治的120例大叶性肺炎患儿的临床资料,根据治疗方式的不同将其分为对照组(60例,阿奇霉素静脉滴注治疗)和观察组(60例,阿奇霉素序贯给药治疗)。比较两组的治疗效果、不良反应情况、血清炎症因子及肺功能指标水平。结果观察组的治疗总有效率显著高于对照组,不良反应总发生率显著低于对照组(P<0.05)。治疗后,两组的TNF-α、PCT、IFN-γ、TM水平均降低,FVC、TLC、Cdyn水平均升高,且观察组显著优于对照组(P<0.05)。结论阿奇霉素序贯给药辅助治疗小儿大叶性肺炎的效果显著,可有效改善患儿血清炎症因子水平和肺功能指标水平,降低不良反应发生率,值得临床推广应用。 相似文献
14.
15.
16.
阐述了孙丽平教授治疗小儿咳嗽临床常用的8组对药,即前胡与白前、紫菀与款冬花、苦杏仁与桃仁、橘红与桔梗、瓜蒌与冬瓜子、地龙与僵蚕、川贝母与浙贝母、沙参与麦冬的配伍特点及临床应用心得,并列举其临证经典医案,结合中药学理论和现代药理学研究,总结分析孙教授运用对药治疗小儿咳嗽的学术经验及用药思路。孙教授认为小儿体属稚阳,其咳多起肺虚实之热,主以清热护肺,次以运脾滋阴,主次同疗,则阴阳平矣,强调小儿咳嗽用药,应以辨别个体体质差异为基础,提倡对药组方"肺脾同治、气血通调、阴阳平补"的用药理念。附案例1则,以资验证。 相似文献
17.
舌癌患者手术及放化疗后会出现构音障碍、吞咽困难、口腔黏膜炎、口干、营养不良等并发症,使患者生存质量下降,甚至导致肿瘤的复发转移,影响生存期,单一方法往往顾此失彼。依托于中国中医科学院西苑医院肿瘤康复基地,杨宇飞教授在国内外调研考察基础上,结合中国国情,构建了一种“门诊多学科肿瘤康复模式”,在舌癌康复方面,以患者为中心,以中医肿瘤内科为主导,多学科共同参与,结合康复科、口腔科、营养科、药剂科等各科优势,形成全程个体化规范序贯康复方案,对患者及早进行康复,在放疗前进行预防性干预尤其重要,使患者能够快速缓解手术和放疗的不良反应,患者获益明显。现取两个典型案例总结其舌癌多学科康复的经验,以期为舌癌的康复提供借鉴。 相似文献
18.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
19.
Peter H. Egbers Anna-Liisa Sutt Jenny E. Petersson Liza Bergström Eva Sundman 《Acta anaesthesiologica Scandinavica》2023,67(10):1403-1413
Background
Weaning from mechanical ventilation and tracheostomy after prolonged intensive care consume enormous resources with optimal management not currently well described. Restoration of respiratory flow via the upper airway is essential and early cuff-deflation using a one-way valve (OWV) is recommended. However, extended OWV use may cause dry airways and thickened secretions which challenge the weaning process. High-flow therapy via the tracheostomy tube (HFT-T) humidifies inspired air and may be connected via an in-line OWV (HFT-T-OWV) alleviating these problems. We aim to provide clinical and experimental data on the safety of HFT-T-OWV along with a practical guide to facilitate clinical use during weaning from mechanical ventilation and tracheostomy.Methods
Data on adverse events of HFT-T-OWV were retrieved from a quality register for patients treated at an intensive care rehabilitation center between 2019 and 2022. Benchtop experiments were performed to measure maximum pressures and pressure support generated by HFT-T-OWV at 25–60 L/min flow using two different HFT-T adapters (interfaces). In simulated airway obstruction using a standard OWV (not in-line) maximum pressures were measured with oxygen delivered via the side port at 1–3 L/min.Results
Of 128 tracheostomized patients who underwent weaning attempts, 124 were treated with HFT-T-OWV. The therapy was well tolerated, and no adverse events related to the practice were detected. The main reason for not using HFT-T-OWV was partial upper airway obstruction using a OWV. Benchtop experiments demonstrated HFT-T-OWV maximum pressures <4 cmH2O and pressure support 0–0.6 cmH2O. In contrast, 1–3 L/min supplemental oxygen via a standard OWV caused pressures between 84 and 148 cmH2O during simulated airway obstruction.Conclusions
Current study clinical data and benchtop experiments indicate that HFT-T-OWV was well tolerated and appeared safe. Pressure support was low, but humidification may enable extended use of a OWV without dry airway mucosa and thickened secretions. Results suggest the treatment could offer advantages to standard OWV use, with or without supplementary oxygen, as well as to HFT-T without a OWV, for weaning from mechanical ventilation and tracheostomy. However, for definitive treatment recommendations, randomized clinical trials are needed. 相似文献20.